Clinical Trials
144 trialsTEMOBIC
Assistance Publique Hopitaux De Marseille
Comparing Telehealth and In-person Assessments in Glioma Patients Receiving Oral Chemotherapy
Mayo Clinic
AB-218-IIT-201
Melbourne Health
Temporally-modulated Pulsed Radiation Therapy (TMPRT) After Prior EBRT for Recurrent IDH-mutant Gliomas
Washington University School of Medicine
Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy (SDT) in Patients With Newly Diagnosed High-Grade Glioma (HGG) Prior to Resection and Standard Adjuvant Therapy (ALA SDT GLIOMA 401)
Universität Münster
CBT-I in PBT
Virginia Commonwealth University
Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma
Mayo Clinic
Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas
Thomas Jefferson University
Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved
Grupo Español de Investigación en Neurooncología
Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma
University of California, San Francisco
RIGEL
Erasmus Medical Center
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
St. Jude Children's Research Hospital
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Memorial Sloan Kettering Cancer Center
HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors
University of Alabama at Birmingham
Social Determinants of Health in Glioblastoma Population
Wake Forest University Health Sciences
Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas
Columbia University
Long Term Implications of Rare Brain Tumours'
University of Leeds
Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors
Mayo Clinic
Clinical Development of Cancer-Specific MRS Biomarkers in Malignant Gliomas
University of Texas Southwestern Medical Center
Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma
Northwestern University
Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors
OHSU Knight Cancer Institute
Safety Study of Afatinib for Brain Cancer
Saint John's Cancer Institute
Antineoplaston Therapy in Treating Children With Brain Tumors
Burzynski Research Institute
Clinical Development of MR Spectroscopy and Imaging in Brain Cancers
University of Texas Southwestern Medical Center
Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors
Wake Forest University Health Sciences
Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors
Wake Forest University Health Sciences
Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
City of Hope Medical Center
Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors
Wake Forest University Health Sciences
Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor
Wake Forest University Health Sciences
Thalidomide and Procarbazine in Treating Patients With Recurrent or Progressive Malignant Glioma
Wake Forest University Health Sciences
SCUSF1202
University of South Florida
Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas
Abramson Cancer Center at Penn Medicine
Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma
Jonsson Comprehensive Cancer Center
BNL
University Hospital, Montpellier
Vaccine Therapy in Treating Young Patients Who Are Undergoing Surgery for Malignant Glioma
Jonsson Comprehensive Cancer Center
Vaccine Therapy in Treating Patients With Malignant Glioma
Jonsson Comprehensive Cancer Center
Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma
Jonsson Comprehensive Cancer Center
Everolimus in Treating Patients With Recurrent Low-Grade Glioma
University of California, San Francisco
Acute Side Effects in Patients Who Are Undergoing Stereotactic Radiosurgery for Brain Tumors or Other Brain Disorders
Case Comprehensive Cancer Center
Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers
Case Comprehensive Cancer Center
Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma
University of California, Davis
Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme
Mayo Clinic
Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma
Memorial Sloan Kettering Cancer Center
Dexanabinol in Patients With Brain Cancer
University of California, San Diego
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Alliance for Clinical Trials in Oncology
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Alliance for Clinical Trials in Oncology
Study of Blood and Cheek Cell Samples From Patients With Glioma
University of California, San Francisco
Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins